This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO 2019

American Society of Clinical Oncology Congress 2019

At the 2019 ASCO meeting, Boehringer Ingelheim presented the latest advances in their cancer research programme across multiple tumour types.

Please see below for more information and downloadable versions of our ASCO publications.

31 May–4 June 2019
McCormick Place Convention Center Chicago, Illinois United States
Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Saturday 1st June
Afatinib* vs methotrexate as second-line treatment for patients with recurrent and/or metastatic head and neck squamous cell carcinoma progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial
Author(s): Guo et al.
Poster Presentation
Tumour Type(s): HNSCC
Presentation Number: 6024
Targeting IGF-1/2 with xentuzumab^ plus enzalutamide in metastatic castration-resistant prostate cancer after progression on docetaxel chemotherapy and abiraterone: Randomized phase II trial results
Author(s): Hussain et al.
Poster Presentation
Tumour Type(s): Prostate cancer
Presentation Number: 5030
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828^ (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors
Author(s): Chong et al.
Poster Presentation
Tumour Type(s): Solid tumours
Presentation Number: TPS3166
There are no publications which meet your criteria on this date
Sunday 2nd June
XENERA™-1: A phase II trial of xentuzumab in combination with everolimus and exemestane in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer and non-visceral involvement
Author(s): Schmid et al.
Poster Presentation
Tumour Type(s): Breast cancer
Presentation Number: TPS1103
Nintedanib** plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO
Author(s): Grohé et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 9074
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

^This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

Page last updated: June 2019